Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9.
Zarza
José
J
D000074:Acenocoumarol / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D000368:Aged; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics* / Q000502:physiology; D001569:Benzodiazepines / Q000008:administration & dosage; D065729:Cytochrome P-450 CYP2C9; D004347:Drug Interactions; D005753:Gastric Mucosa / Q000187:drug effects; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000201:enzymology / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006720:Homozygote; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D002546:Ischemic Attack, Transient / Q000188:drug therapy; D008297:Male; D011110:Polymorphism, Genetic
D001569:Benzodiazepines; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C005245:tetrazepam; D000074:Acenocoumarol; D007213:Indomethacin